Co-Authors
This is a "connection" page, showing publications co-authored by DAVID POPLACK and SUSAN BLANEY.
Connection Strength
1.928
-
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 01; 23(7):1555-63.
Score: 0.253
-
Neoplastic meningitis: diagnosis and treatment considerations. Med Oncol. 2000 Aug; 17(3):151-62.
Score: 0.184
-
New cytotoxic drugs for intrathecal administration. J Neurooncol. 1998 Jun-Jul; 38(2-3):219-23.
Score: 0.159
-
Central nervous system leukemia. Curr Opin Oncol. 1996 Jan; 8(1):13-9.
Score: 0.134
-
Pharmacologic strategies for the treatment of meningeal malignancy. Invest New Drugs. 1996; 14(1):69-85.
Score: 0.134
-
Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. Biochem Pharmacol. 1993 Apr 06; 45(7):1493-501.
Score: 0.111
-
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6.
Score: 0.110
-
Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 1993 Feb 15; 53(4):725-7.
Score: 0.110
-
Modulation of the cytotoxic effect of cyclopentenylcytosine by its primary metabolite, cyclopentenyluridine. Cancer Res. 1992 Jun 15; 52(12):3503-5.
Score: 0.105
-
Current pharmacological treatment approaches to central nervous system leukaemia. Drugs. 1991 May; 41(5):702-16.
Score: 0.097
-
Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park). 1991 May; 5(5):107-16; discussion 123, 127.
Score: 0.097
-
Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates. Cancer Res. 1990 Dec 15; 50(24):7915-9.
Score: 0.095
-
Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 01; 21(1):143-7.
Score: 0.054
-
Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000; 45(3):259-64.
Score: 0.044
-
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
Score: 0.039
-
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr; 15(4):1538-43.
Score: 0.037
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.035
-
A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995 Sep 15; 55(18):4069-72.
Score: 0.033
-
Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol. 1995; 36(2):121-4.
Score: 0.031
-
Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol. 1995 Jan; 13(1):177-9.
Score: 0.031
-
Antiretroviral drug development and clinical pharmacology. Pediatr Infect Dis J. 1991 Nov; 10(11):849-57.
Score: 0.025
-
Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6.
Score: 0.010